Handelnine Global LLC drug recall: Rheumacare capsules
Key facts
- Agency
- U.S. Food and Drug Administration (FDA)
- Program
- Drugs
- Classification
- Class I
- Status
- Ongoing
- Event ID
- 98165
- Recall initiated
- Dec 22, 2025
- Classified by FDA
- Feb 12, 2026
- Posted in Enforcement Report
- Feb 11, 2026
- Recalling firm
- HANDELNINE GLOBAL LLC
- Firm location
- South Plainfield, NJ, United States
- Initiated by
- Voluntary: Firm initiated
- Firm notified customers by
- Press Release
- Products in this event
- 1
What to do
Compare the product, lot or serial numbers below with what you have. If you use a prescription drug or medical device in this recall, talk to your pharmacist or health care provider before you stop using it, and follow the firm's instructions.
Reason for recall
CGMP Deviations: product found to contain lead.
What the classification means
- Class I: FDA's most serious category: there is a reasonable probability that using or being exposed to the product will cause serious health problems or death.
About this recall
The firm started this recall on Dec 22, 2025. FDA classified it 52 days later, on Feb 12, 2026. Distribution reported by FDA: Product was distributed to one customer in NY.
Recalled products (1)
D-0332-2026 Class I Ongoing
Rheumacare capsules, 30 count bottle, Mfg in India by: Virgo UAP Pharma Pvt. Ltd., Ahmedabad, India UPC 8 904218 700313
Codes / lots: Lot: CAM040, Exp. 06/30/2029 Lot: CAL079-N, Exp. 09/30/2028
Quantity: 4 bottles /30 capsules each
Source and freshness
- Source
- U.S. Food and Drug Administration (FDA) Enforcement Report, via the openFDA drug enforcement dataset
- Official notice
- FDA Enforcement Report, event 98165
- Raw record
- openFDA API (JSON)
- Dataset last updated by FDA
- Nov 3, 2026
- Imported by RecallRadar
- Nov 4, 2026
Enforcement Report entries describe recalls FDA has classified. They are not always the same as a company press release. If something here differs from FDA's record, FDA's record is correct — please tell us.